Most emerging companies reach the same crossroads. The science is promising, the first-in-human study is on the horizon, and the board is asking who will own clinical execution. The answer is often nobody, at least not yet. Hiring a full-time Chief Operating Officer or VP of Clinical Operations can take six months and cost more than the company can justify before a financing milestone. That gap is exactly where fractional executive leadership earns its place.

A fractional executive is a seasoned leader who works with your company on a part-time or defined-scope basis. In clinical research, that usually means…

You can outsource execution. You cannot outsource accountability.

That distinction is where many CRO/sponsor partnerships succeed…or unravel.

For a small biotech, hiring a CRO can feel like acquiring a ready-made clinical operations organization, but a CRO is not a substitute for a sponsor-side operating model.

The sponsor still owns…

Sponsors negotiate CRO rates. CRO budgets are not driven by rates.

They are driven by assumptions — about how many sites you will need, how fast they will enroll, how many visits will happen, how long the study will run. The rate card is what gets argued over in contracting. The assumptions are what determine the invoice eighteen months later…

AI is changing clinical data management by automating repetitive review, predicting likely data issues and accelerating medical coding and reconciliation. It will not deliver a zero-query database, and sponsors who expect that are setting themselves up for disappointment. The real gain is shifting data managers from finding errors to understanding them…

Competency frameworks in clinical research tend toward two failure modes. They are either so generic they describe any manager in any industry, or so exhaustive that nobody reads them after the first assessment cycle.

A useful framework for clinical project managers is narrow, observable, and tied to actual study work. Five domains cover most of what matters.

Operational planning is the…

Machine learning can make risk-based quality management more sensitive and timelier, but it also produces more signals than most teams can act on. The value of AI in RBQM depends less on the algorithm and more on how well a sponsor defines what matters and who responds.

Risk-based approaches are now firmly embedded in the regulatory framework. ICH E6(R3) emphasizes quality by design, critical-to-quality factors and proportionate oversight. Centralized monitoring, where data is reviewed remotely for anomalies and trends, is a core tool. It is also…

A well-written MSA and SOW do not manage CRO performance.

They establish the commercial and contractual foundation. But when timelines slip, enrollment assumptions change, site activation stalls, or a critical issue sits unresolved, the contract is rarely what determines the outcome.

Governance does.

Too many sponsors over-index on…

If your governance model produces 12 pages of meeting minutes, but no clear decision, owner, or change in course, it is not operational oversight.  It might be compliance theater.

As organizations implement ICH E6(R3), I worry that some will respond as our industry often does to change: add another meeting, expand the checklist, build another dashboard, and document every discussion in greater detail.

But R3 is not a mandate to create…

More sponsor oversight does not automatically create better CRO oversight or operational excellence.

In biotech, uncertainty often triggers more meetings, trackers, dashboards, action logs, and approval layers. It can feel like control. But it can also create administrative drag while the operational risks most likely to affect patients, data quality, timelines, and delivery receive the same attention as everything else.

A risk-based oversight model asks a more useful question…

Turnover in clinical operations, particularly among clinical research associates and clinical trial managers, remains a persistent constraint on delivery. It disrupts site relationships, erodes study knowledge, and imposes retraining costs that never appear cleanly in a budget line.

Compensation drives some of it and leaders control little of that directly. Several other drivers are within reach.

Workload opacity ranks…

This is an awkward article for a consultant to write, so let me be direct about the conflict: I sell clinical operations consulting. What follows is how I would evaluate someone in my position, including the questions I would find hardest to answer well…

Every CRO proposal now mentions artificial intelligence. The question for sponsors is not whether a CRO uses AI, but whether that AI will make a measurable difference on your specific study. Answering that requires asking better questions during CRO selection than most sponsors currently ask.

Having sat on both sides of the bid defense table, I can tell you that AI slides are often…

Many biotech and emerging biopharma sponsors are treating ICH E6(R3) as a documentation update:  new templates, new signatures, same relationship with the CRO underneath. That reading will not survive an inspection. R3 says accountability cannot be delegated. Whatever the CRO does, the sponsor still owns trial quality and participant safety, and a CRO's failure shows up as the sponsor's finding.

That changes three things that are currently on autopilot…

On June 3, 2026, the final ICH E6(R3) Good Clinical Practice Annex 2 was adopted and officially published by the International Council for Harmonisation.

With Annex 1 already moving into implementation, Annex 2 completes the updated global GCP framework. And for biotech and emerging biopharma, this is a signal that the operating model for clinical research must evolve…

For lean biotech and emerging biopharma teams, ICH E6(R3)’s risk-based approach is an invitation to spend deliberately. You do not need to monitor every site, data point, activity, and process with the same intensity. The goal is proportionality.  To focus oversight where failure could genuinely compromise participant safety, rights, wellbeing, or the reliability of the data needed to make a development decision.

A proportional monitoring plan starts with…

The default assumption at most first-time sponsors is that a clinical trial requires a CRO, and that the only question is which one. For a Phase 1 study, that assumption is worth testing before it costs you anything.

An experienced Phase 1 unit is not simply a site. For a single-center first-in-human study it typically provides…

Artificial intelligence is already reshaping parts of clinical operations. Site identification, enrollment forecasting, risk signal detection, document drafting, and query generation are all being automated or augmented. The question for clinical leaders is which parts of their role this touches.

The work that compresses is largely the synthesis and monitoring layer. Producing a status summary from multiple system exports, identifying outlier sites from monitoring data, drafting a first version of a study plan, and scanning for protocol deviation patterns are all tasks where a capable model plus a competent reviewer outperforms the manual process on speed and often on coverage. Leaders who spend…

AI-driven site feasibility can improve how sponsors shortlist clinical trial sites, but it cannot replace a conversation with the people who will actually run the study. Predictive models are strong at pattern recognition across historical performance data. They are weak at detecting what changed last month.

Site selection has always been one of the most consequential and least…